Cue biopharma reports fourth quarter and full year 2020 financial results and recent business highlights

Cambridge, mass., march 16, 2021 (globe newswire) -- cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted t cells directly within the patient's body, provided a business update for the fourth quarter and full year 2020.
CUE Ratings Summary
CUE Quant Ranking